Qiagen N.V. (QGEN)
Healthcare • Diagnostics & Research
StockNYSENetherlandsNL0015002SN0
49.99 USD
-0.22% today Updated 13 Nov 2026 16:26
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Qiagen N.V., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
03 Feb 2027
in 82 days · 16:00 · estimate 0.59
Last results
0.65 vs 0.63 estimated
03 Nov 2026 · Beat +3.6%
Beat the estimate
7 of 12
1 missed · 4 in line · 2 beats in a row
Average surprise
+2.7%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 03 Feb 2027 16:00 | 0.59 | — | — | Upcoming |
| 03 Nov 2026 19:00 | 0.63 | 0.65 | +3.6% | Beat |
| 04 Aug 2026 20:00 | 0.60 | 0.62 | +3.5% | Beat |
| 05 May 2026 20:00 | 0.54 | 0.54 | 0.0% | In line |
| 04 Feb 2026 16:00 | 0.62 | 0.62 | +0.1% | In line |
| 04 Nov 2025 15:00 | 0.62 | 0.64 | +4.1% | Beat |
| 05 Aug 2025 16:00 | 0.63 | 0.63 | -0.5% | In line |
| 07 May 2025 16:00 | 0.54 | 0.58 | +8.1% | Beat |
| 05 Feb 2025 16:00 | 0.65 | 0.64 | -1.3% | Miss |
| 06 Nov 2024 23:00 | 0.59 | 0.62 | +3.8% | Beat |
| 30 Jul 2024 20:00 | 0.56 | 0.60 | +6.0% | Beat |
| 28 Apr 2024 20:00 | 0.47 | 0.50 | +5.1% | Beat |
| 05 Feb 2024 19:00 | 0.60 | 0.60 | -0.7% | In line |
| 30 Oct 2023 16:00 | 0.54 | 0.56 | +3.4% | Beat |
| 08 Aug 2023 01:00 | 0.56 | 0.57 | +1.5% | Beat |
| 02 May 2023 20:00 | 0.51 | 0.57 | +10.9% | Beat |
| 10 Feb 2023 06:00 | 0.52 | 0.59 | +13.6% | Beat |
| 07 Nov 2022 16:00 | 0.51 | 0.59 | +16.6% | Beat |
| 26 Jul 2022 13:00 | 0.51 | 0.57 | +12.3% | Beat |
| 27 Apr 2022 16:00 | 0.80 | 0.89 | +11.7% | Beat |
| 08 Feb 2022 16:00 | 0.68 | 0.83 | +21.9% | Beat |
| 03 Nov 2021 16:00 | 0.60 | 0.65 | +8.3% | Beat |
| 29 Jul 2021 16:00 | 0.74 | 0.75 | +1.7% | Beat |
| 03 May 2021 16:00 | 0.70 | 0.74 | +4.7% | Beat |
| 09 Feb 2021 16:00 | 0.71 | 0.76 | +7.1% | Beat |
| 27 Oct 2020 15:00 | 0.62 | 0.65 | +4.2% | Beat |
| 04 Aug 2020 16:00 | 0.54 | 0.61 | +14.5% | Beat |
| 06 May 2020 17:00 | 0.30 | 0.38 | +28.1% | Beat |
| 04 Feb 2020 16:00 | 0.49 | 0.54 | +8.8% | Beat |
| 30 Oct 2019 16:00 | 0.39 | 0.40 | +2.9% | Beat |
| 24 Jul 2019 16:00 | 0.37 | 0.37 | -0.4% | In line |
| 08 May 2019 06:00 | 0.29 | 0.30 | +4.4% | Beat |
| 04 Feb 2019 16:00 | 0.44 | 0.45 | +0.8% | In line |
| 29 Oct 2018 16:00 | 0.37 | 0.39 | +5.8% | Beat |
| 31 Jul 2018 16:00 | 0.36 | 0.37 | +3.5% | Beat |
| 02 May 2018 16:00 | 0.27 | 0.29 | +6.7% | Beat |
| 31 Jan 2018 16:00 | 0.46 | 0.48 | +3.9% | Beat |
| 06 Nov 2017 16:00 | 0.36 | 0.36 | -1.2% | Miss |
| 27 Jul 2017 11:00 | 0.32 | 0.33 | +5.7% | Beat |
| 02 May 2017 16:00 | 0.23 | 0.22 | -2.9% | Miss |
| 01 Feb 2017 17:00 | 0.43 | 0.44 | +1.3% | Beat |
| 02 Nov 2016 16:00 | 0.32 | 0.34 | +5.4% | Beat |
| 28 Jul 2016 16:00 | 0.25 | 0.28 | +9.2% | Beat |
| 29 Apr 2016 06:00 | 0.22 | 0.22 | -1.7% | Miss |
| 02 Feb 2016 16:00 | 0.37 | 0.36 | -3.1% | Miss |
| 28 Oct 2015 16:00 | 0.32 | 0.34 | +4.5% | Beat |
| 29 Jul 2015 16:00 | 0.29 | 0.30 | +2.2% | Beat |
| 05 May 2015 16:00 | 0.25 | 0.26 | +1.7% | Beat |
| 28 Jan 2015 16:00 | 0.33 | 0.29 | -11.9% | Miss |
| 29 Oct 2014 16:00 | 0.31 | 0.31 | +0.6% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.1B | +5.7% | 424.9M | 20.3% | 2.04 | +409.8% | 447.2M |
| 2024 | 2B | +0.7% | 83.6M | 4.2% | 0.40 | -75.7% | 502.3M |
| 2023 | 2B | -8.2% | 341.3M | 17.4% | 1.65 | -19.6% | 296.7M |
| 2022 | 2.1B | — | 423.2M | 19.8% | 2.05 | — | 565.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 50.50 | 50.97 | 49.95 | 49.99 | -0.46% | 40,168,264 | |
| Oct 2026 | 43.85 | 50.82 | 41.94 | 50.22 | +14.76% | 119,487,200 | |
| Sep 2026 | 44.23 | 45.53 | 41.74 | 43.76 | +1.09% | 40,762,600 | |
| Aug 2026 | 42.28 | 45.53 | 40.87 | 43.29 | +4.57% | 70,052,700 | |
| Jul 2026 | 39.38 | 44.03 | 37.69 | 41.40 | +5.88% | 63,097,700 | 0.3500 |
| Jun 2026 | 36.15 | 39.90 | 35.46 | 39.10 | +6.86% | 52,607,700 | |
| May 2026 | 34.84 | 37.04 | 32.53 | 36.59 | +5.81% | 43,674,300 | |
| Apr 2026 | 40.27 | 42.33 | 33.17 | 34.58 | -13.64% | 41,786,500 | |
| Mar 2026 | 48.80 | 49.71 | 38.80 | 40.04 | -19.60% | 46,491,100 | |
| Feb 2026 | 52.45 | 53.30 | 47.37 | 49.80 | -7.21% | 40,676,300 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck (opens in a new tab) 12 Nov 2026 15:00
- RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics (opens in a new tab) 12 Nov 2026 14:06
- Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate (opens in a new tab) 11 Nov 2026 14:21
- Human Identification - Global Strategic Business Report 2026: Capitalize on 10.1% CAGR to $1.9 Billion by 2032 | Thermo Fisher, Illumina, Qiagen and Bio-Rad Vie for Shares (opens in a new tab) 11 Nov 2026 14:15
- Epigenetics - Global Strategic Business Report: Capitalize on an 18.2% CAGR to Secure the $5.5 Billion 2030 Market as Illumina, Thermo Fisher Scientific, Qiagen, and Bio-Rad Disrupt Precision Medicine (opens in a new tab) 11 Nov 2026 14:12
- Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director (opens in a new tab) Simply Wall St. · 11 Nov 2026 12:17
- Electrophoresis Reagents - Global Strategic Business Report: Capitalize on China's 7.4% CAGR as Bio-Rad, QIAGEN, Agilent, Merck Millipore and Thermo Fisher Battle for $1.3B by 2032 (opens in a new tab) 10 Nov 2026 15:09
- Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share (opens in a new tab) 10 Nov 2026 15:02
- Gene Panels - Global Strategic Business Report 2026: Capitalize on 17.9% CAGR as Market Triples to $12.6B by 2032 - Track Key Players Illumina, Roche, QIAGEN, Thermo Fisher, Agilent and More (opens in a new tab) 10 Nov 2026 14:24
- Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN (opens in a new tab) 10 Nov 2026 14:19
- Global DNA and Genomic Profiling Kits Market Report 2026 | Capture the $2.09B Market by 2030 | Features Profiles of Thermo Fisher, Illumina, QIAGEN and More (opens in a new tab) 10 Nov 2026 14:14
- Global Genome Annotation Services Market Report 2026: Trends and Forecast to 2030 | Capitalize on AI and Precision Medicine with Roche, Thermo Fisher, Illumina, QIAGEN (opens in a new tab) 09 Nov 2026 14:33
- Large Language Model (LLM)-Powered Genomic Report Drafting Global Market Report 2026 | Capitalize on 23.6% CAGR Through 2030 with Illumina, QIAGEN, Tempus AI and SOPHiA GENETICS (opens in a new tab) 09 Nov 2026 14:28
- Genomic Variant Prioritization Artificial Intelligence (AI) Global Market Report 2026 | Capitalize on 26.5% CAGR with Illumina, QIAGEN, Thermo Fisher Scientific and Tempus AI (opens in a new tab) 09 Nov 2026 14:26
- Global Ribonucleic Acid (RNA) Extraction Kits Market Report 2026 | Capitalize on 10.1% CAGR to $3.68B by 2030 as Roche, Thermo Fisher, QIAGEN and Merck Accelerate Automation (opens in a new tab) 09 Nov 2026 14:25
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 50.10 USD
- Market cap
- 10.3B
- Dividend yield
- 0.70%
- Payout ratio
- 19%
- Last dividend
- 0.3500 USD · 07 Jul 2026
- Exchange
- NYSE
- Country
- Netherlands
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 07 Jul 2026 | 0.3500 USD |
| 02 Jul 2025 | 0.2500 USD |
| 30 Jan 2024 | 1.3577 USD |
| 25 Jan 2017 | 1.1539 USD |
| 2 older dividends: create a free account to see them | |
Why this score
Similar shares
Follow QGEN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.